Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The AML Channel

Explore the latest updates, including expert interviews, features, podcasts and e-learning
Latest Videos The AML Sessions Conferences Topics Features Podcasts Expert Editorial Board

Welcome to The Acute Myeloid Leukemia (AML) Channel

VJHemOnc brings you the latest and greatest global advances related to the classification, diagnosis, treatment, and management of AML. Speaking with world-leading experts, The AML Channel delivers video interviews, podcasts, roundtable discussions, and more.

Hot topics frequently covered on The AML Channel include the use of measurable residual disease (MRD) testing to guide treatment, targeted agents, and CAR T-cell therapies.

Conferences

iwAL 2026
SOHO 2026
EHA 2026
ASCO 2026
EBMT 2026
ESH AL 2026
19:38
Novel targets, combinations, and treatments in AML: insights from iwAL 2026
Gail Robozet al. • 7 Oct 2026
18:47
Insights into established therapies in AML: OPTI-AML & the future of combination therapy
Andrew Weiet al. • 20 Sep 2026
6:18
Differentiation syndrome in menin inhibitor-treated patients: recognition, management & next steps
Eunice Wanget al. • 18 Sep 2026
12:28
Targeting FLT3-mutant AML: frontline strategy, MRD-guided transplant, and RAS-targeted approaches
Alexander Perlet al. • 20 Sep 2026
View All Videos
4:14
Lessons from Phase I KITE-222: antigen escape, expansion, and the future of CAR-T in AML
David Sallman • 1 Oct 2026
3:29
ICUS, CHIP, and CCUS: practical approaches to diagnosis, risk stratification, and referral
Zhuoer Xie • 11 Sep 2026
2:18
Can current MRD assays accurately predict relapse in AML? Limitations and future directions
Farhad Ravandi • 21 Sep 2026
1:09
Will MRD eradication become a routine treatment goal in AML?
Farhad Ravandi • 21 Sep 2026
View All Videos
0:56
Guidance for community oncologists treating patients with relapsed IDH1-mutated AML
Agnieszka Wierzbowska • 12 Jun 2026
1:45
Q-TWiST analysis from the QUANTUM-First trial: evaluating quality-adjusted survival in AML
Esther Oliva • 25 Jun 2026
0:59
Prognostic value of pre-treatment health-related QoL indicators in AML: analysis from EORTC AML21
Fabio Efficace • 12 Jun 2026
1:19
Key advances shaping frontline treatment for AML
Amir Fathi • 13 Jun 2026
View All Videos
3:36
How do fewer chemotherapy plus venetoclax consolidation cycles impact toxicity and efficacy in AML?
Jennifer Marvin-Peek • 5 Jun 2026
1:44
Molecular testing and managing patients with AML: advice for community clinicians
Jennifer Marvin-Peek • 1 Jun 2026
1:56
Key diagnostic and therapeutic challenges in TP53-mutated MDS, AML, and MPNs
Akriti Jain • 27 Jun 2026
2:00
Findings from a Phase Ib/II trial assessing azacitidine, venetoclax & ivosidenib in IDH1-mutated AML
Akriti Jain • 27 Jun 2026
View All Videos
2:35
Older matched sibling donor vs young haploidentical donor for alloSCT in secondary AML in CR1
Arnon Nagler • 20 Mar 2026
4:39
Promising approaches for optimizing transplant conditioning in AML
Arnon Nagler • 20 Mar 2026
1:48
Non-HLA-matched pooled umbilical cord blood transplant in acute leukemias and MDS
Filippo Milano • 18 Mar 2026
5:36
Total marrow and lymphoid irradiation with PTCy-based GvHD prophylaxis in patients with AML
Anthony Stein • 31 Mar 2026
View All Videos
7:48
MRD as a surrogate endpoint in AML: challenges, ongoing studies, and the need to standardize assays
Harry Erba • 28 Feb 2026
1:37
Why TP53-mutated AML is so therapeutically challenging: an insight into disease biology
Thomas Cluzeau • 27 Feb 2026
1:04
TP53-mutated AML: clinical outcomes with azacitidine-based therapy
Thomas Cluzeau • 27 Feb 2026
1:36
Treatment approaches for patients with IDH1-mutated AML & practical considerations
Thomas Cluzeau • 28 Feb 2026
View All Videos

Topics

MRD
Transplant
CAR-T & Cellular Therapy
Real-World Data
Trial Updates
Immuno-Oncology
11:47
Managing FLT3-ITD mutant AML in remission
Eunice Wang • 19 Sep 2026
12:28
Targeting FLT3-mutant AML: frontline strategy, MRD-guided transplant, and RAS-targeted approaches
Alexander Perlet al. • 20 Sep 2026
14:04
MRD as a clinical endpoint in trials for AML: updates from recent datasets
Gege Gui • 18 Sep 2026
13:26
Circulating tumor DNA enables sensitive and universally applicable MRD monitoring in AML
Tian Yi Zhang • 18 Sep 2026
View All Videos
11:47
Managing FLT3-ITD mutant AML in remission
Eunice Wang • 19 Sep 2026
12:28
Targeting FLT3-mutant AML: frontline strategy, MRD-guided transplant, and RAS-targeted approaches
Alexander Perlet al. • 20 Sep 2026
8:10
Incorporating venetoclax into intensive chemotherapy-based induction in ND AML
Courtney DiNardo • 19 Sep 2026
12:41
Telomere dynamics in normal and pathological aging
Coleman Lindsley • 18 Sep 2026
View All Videos
10:42
SENTI-202: a first-in-class logic-gated off-the-shelf CAR NK-cell therapy for R/R AML
Stephen Strickland • 19 Sep 2026
13:39
AVC-201: a CAR-T using a switchable module in AML
Marion Subklewe • 19 Sep 2026
4:14
Lessons from Phase I KITE-222: antigen escape, expansion, and the future of CAR-T in AML
David Sallman • 1 Oct 2026
17:01
Emerging immunotherapy strategies in AML: CAR-T, NK cells and T-cell engagers
David Sallmanet al. • 20 Sep 2026
View All Videos
2:33
Real-world data support olutasidenib after venetoclax in IDH1-mutated AML
Pinkal Desai • 12 Jun 2026
1:35
Guidance for community oncologists navigating the AML treatment landscape
Yakir Moshe • 13 Jun 2026
2:44
Insights into the real-world REVIVE study: venetoclax-based low-intensity therapy in AML
Yakir Moshe • 13 Jun 2026
3:26
EBMT analysis: alloSCT may overcome FLT3-ITD risk in CBFB::MYH11-positive AML
Arnon Nagler • 15 Jun 2026
View All Videos
19:38
Novel targets, combinations, and treatments in AML: insights from iwAL 2026
Gail Robozet al. • 7 Oct 2026
10:42
SENTI-202: a first-in-class logic-gated off-the-shelf CAR NK-cell therapy for R/R AML
Stephen Strickland • 19 Sep 2026
13:39
AVC-201: a CAR-T using a switchable module in AML
Marion Subklewe • 19 Sep 2026
9:47
Paradigm shift with menin inhibitor triplets: moving beyond older/unfit AML
Joshua Zeidner • 20 Sep 2026
View All Videos
10:42
SENTI-202: a first-in-class logic-gated off-the-shelf CAR NK-cell therapy for R/R AML
Stephen Strickland • 19 Sep 2026
13:39
AVC-201: a CAR-T using a switchable module in AML
Marion Subklewe • 19 Sep 2026
4:14
Lessons from Phase I KITE-222: antigen escape, expansion, and the future of CAR-T in AML
David Sallman • 1 Oct 2026
17:01
Emerging immunotherapy strategies in AML: CAR-T, NK cells and T-cell engagers
David Sallmanet al. • 20 Sep 2026
View All Videos

david-sallman
David Sallman
MD
H. Lee Moffitt Cancer Center & Research Institute
paresh-vyas
Paresh Vyas
MRCP, FRCP, FRCPath
Weatherall Institute of Molecular Medicine, University of Oxford
thomas-cluzeau
Thomas Cluzeau
MD, PhD
Central University Hospital of Nice
eunice-wang
Eunice Wang
MD
Roswell Park Comprehensive Cancer Center
eytan-stein
Eytan Stein
MD
Memorial Sloan Kettering Cancer Center

If you are interested in becoming a supporter of The Acute Myeloid Leukemia Channel, please contact us.

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals